REG - Eco Animal Health Gp - Issue of Equity and Total Voting Rights

ECO Animal HealthAnnouncement

06/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230606:nRSF6885Ba&default-theme=true

RNS Number : 6885B  Eco Animal Health Group PLC  06 June 2023

6 June 2023

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Issue of Equity and Total Voting Rights

 

ECO Animal Health Group plc, a leader in the development, registration and
marketing of pharmaceutical products for global animal health markets,
confirms that a former employee has exercised options over 22,973 ordinary
shares of 5 pence each ("Ordinary Shares") under the Company's Deferred Bonus
Scheme.

Application has been made to the London Stock Exchange for 22,973 new Ordinary
Shares to be admitted to trading on AIM. Admission and dealings in the new
Ordinary Shares is expected to occur at 8.00 a.m. on 9 June 2023.

The new Ordinary Shares will rank pari passu with the existing Ordinary
Shares.

Total Voting Rights

Following Admission, the Company's total issued share capital will consist of
67,744,889 Ordinary Shares with one voting right per share. The Company does
not hold any Ordinary Shares in treasury. The total number of voting rights in
the Company is therefore 67,744,889.

The above figure of 67,744,889 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the Company under
the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries

 ECO Animal Health Group plc                                    0208 447 8899
 David Hallas (CEO)
 Chris Wilks (CFO)

 IFC Advisory                                                   0203 934 6630
 Graham Herring / Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)      0207 496 3051
 Phil Davies / George Tzimas / Sam Butcher

 Investec (Joint Broker)                                        0207 597 5970
 Gary Clarence / Daniel Adams / Carlo Spingardi

 Equity Development                                             0207 065 2692
 Hannah Crowe / Matt Evans

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEADKSEDPDEFA